ClinicalTrials.gg
CompletedNCT04886596Updated Jul 31, 2025Results posted

Efficacy Study of GSK's Investigational Respiratory Syncytial Virus (RSV) Vaccine in Adults Aged 60 Years and Above

A Phase 3 interventional study of Placebo and RSVPreF3 OA vaccine in Respiratory Syncytial Virus Infections, sponsored by GlaxoSmithKline. Completed at 277 sites in 17 countries. Open to participants aged 60 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-31.

Sponsored by GlaxoSmithKline · Phase 3, Interventional, and Prevention

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
26,675
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 17 studies testing arexvy in Respiratory Syncytial Virus Infections — 1 open to participants now, 5 under way, 4 of them phase 3. arexvy · Respiratory Syncytial Virus Infections.

Enrollment
Largest of 17
26,675 · median 976
Started
2021
with 3 others
Phase 3
15 of 17
none open now
Registered
3rd of 17
by date
Lead sponsor
15 of 17
GlaxoSmithKline

Among the 17 studies testing arexvy in Respiratory Syncytial Virus Infections, this one has the largest enrollment, is one of 4 that started in 2021, is one of 15 in phase 3, and was the 3rd registered.

Respiratory Syncytial Virus Infections

306 studies on the registry are indexed under Respiratory Syncytial Virus Infections; 49 are open to participants now.

Browse Respiratory Syncytial Virus Infections studies →

Open to participants now

1 of the 17 studies testing arexvy in Respiratory Syncytial Virus Infections is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About arexvy

No approval found in the FDA or EMA files read. How studies give it is on its page →

Who these studies take

Of the 29 Respiratory Syncytial Virus Infections studies recruiting now, 14 (48%) set no upper age limit and 11 (38%) stop at 75 or younger; 13 take children under 18; 8 take healthy volunteers.

This study: 60 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing arexvy in Respiratory Syncytial Virus Infections, or all of them as a file.
02

Study summary

This study will evaluate the efficacy of the RSVPreF3 OA investigational vaccine in preventing Lower Respiratory Tract Disease (LRTD) caused by RSV in adults ≥60 years of age following a single dose of the RSVPreF3 OA vaccine and following annual revaccination doses in Northern Hemisphere (NH) and in Southern Hemisphere (SH). This study will also assess if the vaccine is safe and induces an immune response.

Read the detailed description

Dose 1 Period will be conducted in 2 parts: Part 1: Participants in RSVPreF3 groups will receive lots 1, 2 and 3 of the investigational vaccine before Season 1. Part 2: Will be initiated when the vaccine lots in part 1 are exhausted at the study sites and participants in RSVPreF3 group will receive lot 4 of the investigational vaccine before Season 1.

03

Conditions studied

  • Respiratory Syncytial Virus Infections

Keywords

  • Respiratory syncytial virus
  • Lower respiratory tract disease
  • Efficacy study
  • Adults aged 60 years and above
04

Who can participate

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • A male or female ≥ 60 YOA at the time of first vaccination, who live in the community (community dwelling participants) or in a long-term care facility (LTCF participants).
  • Participants who, in the opinion of the investigator, can and will comply with the requirements of the protocol.

Note: In case of physical incapacity that would preclude the self-completion of the diary cards and/or questionnaires, either site staff can assist the participant (for activities performed during site visits) or the participant may assign a caregiver to assist him/her with this activity (for activities performed at home or in the LTCF). However, at no time, the site staff or caregiver will evaluate the participant's health status while answering diaries and/or questionnaires or make decisions on behalf of the participant

  • Written or witnessed obtained from the participant prior to performance of any study specific procedure.
  • Participants who are medically stable in the opinion of the investigator at the time of first vaccination. Participants with chronic stable medical conditions with or without specific treatment, such as diabetes, hypertension or cardiac disease, are allowed to participate in this study if considered by the investigator as medically stable.

Exclusion criteria

Exclusion Criteria:

Medical conditions

  • Any confirmed or suspected or immunodeficient condition resulting from disease or immunosuppressive/cytotoxic therapy, based on medical history and physical examination (no laboratory testing required).
  • History of any reaction or likely to be exacerbated by any component of the vaccine.
  • Hypersensitivity to latex.
  • Serious or unstable chronic illness.
  • Any history of dementia or any medical condition that moderately or severely impairs cognition.

Note: If deemed necessary for clinical evaluation, the investigator can use tools such as (MMSE), Mini-Cog or Montreal Cognitive Assessment (MoCA) to determine cognition levels of the participant.

  • Recurrent or un-controlled neurological disorders or seizures. Participants with medically-controlled active neurological diseases can be enrolled in the study as per investigator assessment, provided that their condition will allow them to comply with the requirements of the protocol.
  • Significant underlying illness that in the opinion of the investigator would be expected to prevent completion of the study.
  • Any medical condition that in the judgment of the investigator would make intramuscular injection unsafe.

Prior/Concomitant therapy

  • Use of any or non-registered product (drug, vaccine or medical device) other than the study vaccine during the period beginning 30 days before the first study vaccine administration, or planned use during the study period.
  • Planned or actual administration of a vaccine not foreseen by the study protocol in the period starting 30 days before each dose and ending 30 days after each dose of study vaccine administration, with the exception of inactivated and subunit influenza vaccines which can be administered up to 14 days before or from 14 days after each study vaccination.
  • Previous vaccination with an RSV vaccine.
  • Administration of long-acting immune-modifying drugs or planned administration at any time during the study period.
  • Administration of immunoglobulins and/or any blood products or plasma derivatives during the period starting 90 days before the first study vaccine or planned administration during the study period.
  • Chronic administration (defined as more than 14 consecutive days in total) of immunosuppressants or other immune-modifying drugs during the period starting 90 days prior to the first study vaccine administration or planned administration during the study period. For , this will mean prednisone ≥20 mg/day, or equivalent. Inhaled and topical steroids are allowed.

Prior/Concurrent clinical study experience

  • Concurrently participating in another clinical study, at any time during the study period, in which the participant has been or will be exposed to an investigational or a non-investigational vaccine/product (drug or medical device).

Other exclusions

  • History of chronic alcohol consumption and/or drug abuse as deemed by the investigator to render the potential participant unable/unlikely to provide accurate safety reports or comply with study procedures.
  • Bedridden participants.
  • Planned move during the study period that will prohibit participating in the trial until study end. This includes:

    • Planned move during the study period to another LTCF that will prohibit participation in the trial until study end.
    • Planned move from the community to a LTCF that will prohibit participation in the trial until study end.
  • Participation of any study personnel or their immediate dependants, family, or household members.
  • Planned leave or holiday of 4 consecutive weeks or more during the RSV seasons* covered by the study, that would prohibit the reporting of ARI cases and attendance to ARI visit.

    • RSV seasons are from October to April in NH and from March to September in SH.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

MMSE and MoCA

Short tests of memory and thinking, each scored out of 30. Lower scores suggest more difficulty; criteria give a range, either to include people with memory problems or to leave them out.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
26,675 participants (actual)

Study arms

  • Experimental
    RSVPreF3 Group

    Participants received a single dose of the RSVPreF3 OA vaccine at Day 1. Before the second vaccination participants in this group were re-randomized into 2 as: a group that received placebo every subsequent year, and a group that received an additional dose of RSVPreF3 OA vaccine every subsequent year of the study.

    Biological: RSVPreF3 OA vaccine

  • Placebo comparator
    Placebo Group

    Participants received 1 dose of placebo at Day 1 and an additional dose of placebo every subsequent year of the study.

    Biological: Placebo

Interventions

  • BiologicalPlacebo

    Placebo administered intramuscularly into the deltoid of the non-dominant arm at day 1 and before Season 2 to the Placebo Group, and before Season 2 to the participants of the RSVPreF3 Group, that are re-randomized to the RSV\_1 dose group.

  • RSVPreF3 OA vaccine administered intramuscularly into the deltoid of the non-dominant arm at Day 1 in the RSVPreF3 group, and before Season 2 to the participants of the RSVPreF3 group that are re-randomized to the RSV\_annual group.

06

What researchers measure

Primary outcomes

  1. Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated Lower Respiratory Tract Disease (LRTD) During the First Season Following a Single Dose of the RSVPreF3 OA Vaccine

    First episode of Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)-confirmed RSV A and/or RSV B- associated LRTD during the first season was assessed. The case definition for RSV-confirmed LRTD is as follows: Presence of at least one RSV-positive swab detected by RT-PCR.

    Time frame: From Day 15 post-vaccination up to end of season 1 in the Northern Hemisphere (NH) [a median of approximately 6.7 months (6.9 months in NH and 3.5 months in Southern Hemisphere [SH])]

Secondary outcomes

  1. Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD Over Several Seasons Following a Single Dose of the RSVPreF3 OA Vaccine

    Efficacy of a single dose of the RSVPreF3 OA vaccine was assessed against RSV A and/or B confirmed LRTD over several seasons according to the case definition.

    Time frame: From Day 15 post first vaccination up to end of season 2 and up to end of season 3 in the Northern Hemisphere [NH] (assessed approximately over 2 and 3 years in NH)

  2. Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD Over Several Seasons Following Annual Revaccination Doses of the RSVPreF3 OA Vaccine

    Efficacy of annual revaccination doses of the RSVPreF3 OA vaccine was assessed against RSV A and/or B confirmed LRTD over several seasons according to the case definition.

    Time frame: From Day 15 post first vaccination up to end of season 2 and up to end of season 3 in the NH (assessed approximately over 2 and 3 years in NH)

  3. Number of Participants With First Episode of RT-PCR Confirmed RSV Subtype A and Subtype B LRTD Over 3 Seasons Following a Single Dose of the RSVPreF3 OA Vaccine

    Efficacy of a single dose of the RSVPreF3 OA vaccine was assessed against LRTD episode caused by RSV A and B subtype over 3 seasons according to the case definition.

    Time frame: From Day 15 post first vaccination up to end of season 3 in the NH (assessed approximately over 3 years in NH, and 2.5-3 years in SH)

  4. Number of Participants With First Episode of RT-PCR Confirmed RSV Subtype A and Subtype B LRTD Over 3 Seasons Following a Single Dose of the RSVPreF3 OA Vaccine and Following 1 Annual Revaccination Dose

    Efficacy of a single dose and 1 annual revaccination dose of the RSVPreF3 OA vaccine was assessed against LRTD episode caused by RSV A and B subtype over 3 seasons according to the case definition.

    Time frame: From Day 15 post first vaccination up to end of season 3 in the NH (assessed approximately over 3 years in NH, and 2.5-3 years in SH)

  5. Number of Participants With First Episode of RT-PCR Confirmed LRTD Caused by Human Metapneumovirus (hMPV) up to the End of Season 1 Following a Single Dose of the RSVPreF3 OA Vaccine

    Time frame: From Day 15 post-vaccination up to end of season 1 in the SH [a median of approximately 11.5 months (11.6 months in NH and 9.1 months in SH)]

  6. Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD, by Age Categories Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses

    Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses was assessed against RSV A and/or B confirmed LRTD episode according to the case definition, in the following age categories: greater than or equal to (≥) 65 years of age (YOA), ≥70 YOA and ≥80 YOA.

    Time frame: From Day 15 post first vaccination up to end of season 3 in the NH (assessed approximately over 3 years in NH and 2.5-3 years in SH)

  7. Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by RSV Season Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses

    Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses was assessed against RSV A and/or B confirmed LRTD episode according to the case definition, by RSV season as follows: VE after each season includes the first occurrence of episodes reported from Day 15 post vaccination at first season, and for the next seasons, excluding analysis of participants who already reported a case in the previous season. The RSV season may be extended based on epidemiology data.

    Time frame: From Day 15 post first dose or start of the RSV season to the first occurrence of RSV-confirmed LRTD at each RSV season (assessed approximately over 7 months at each season [Seasons 1 and 2 in SH, Seasons 1, 2 and 3 in NH])

  8. Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by Year Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses

    Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses was assessed against RSV A and/or B confirmed LRTD episode according to the case definition, by years after vaccination as follows: VE at each year includes the first occurrence of episodes reported from Day 14 post vaccination at first year, and for the next years, excluding analysis of participants who already reported a case in the previous year.

    Time frame: From Day 15 post first dose and each revaccination dose up to next dose or end of study (assessed approximately over a year after each vaccination [at Year 1, Year 2 and Year 3])

  9. Number of Participants With First Episode of RT-PCR Confirmed RSV A and /or B Associated LRTD, Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses

    Time frame: From Day 15 post first dose to the first occurrence of RSV LRTD (assessed approximately over 3 years in the NH and 2.5-3 years in SH)

  10. Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by Baseline Comorbidities Using Charlson Comorbidity Index Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses

    Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses is assessed against RSV A and/or B associated LRTD episode by baseline comorbidities using Charlson Comorbidity Index. Low/medium Risk = Participants with co-morbidity score at baseline less than or equal to 3 (Charlson Index); High Risk = Participants with co-morbidity score at baseline greater than 3 (Charlson Index).

    Time frame: From Day 15 post first vaccination up to end of season 3 in the NH (assessed approximately over 3 years in NH and 2.5-3 years in SH)

  11. Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by Baseline Comorbidities According to Comorbidities of Interest Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses

    Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses is assessed against RSV A and/or B associated LRTD episode by baseline comorbidities of interest divided into 2: cardiorespiratory conditions such as chronic obstructive pulmonary disease (COPD), asthma, any chronic respiratory or pulmonary disease, and endocrinometabolic conditions such as diabetes mellitus type 1 or 2, chronic heart failure and advanced liver or renal disease.

    Time frame: From Day 15 post first vaccination up to end of season 3 in the NH (assessed approximately over 3 years in NH and 2.5-3 years in SH)

  12. Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by Baseline Frailty Status Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses

    Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses is assessed against RSV A and /or B associated LRTD episode according to the case definition, by baseline frailty status of frail, pre-frail and fit. Frail = Participants with a walking speed of less than (\<) 0.4 meters per second (m/s) or who were not able to perform the test; Pre-Frail = Participants with a walking speed between 0.4-0.99 m/s; Fit = Participants with a walking speed of ≥1 m/s.

    Time frame: From Day 15 post first vaccination up to end of season 3 in the NH (assessed approximately over 3 years in NH and 2.5-3 years in SH)

  13. Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated Severe LRTD Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses

    Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses is assessed against RSV A and/or B associated severe LRTD episode. Case definition for RSV-confirmed severe LRTD: An RT-PCR confirmed case of RSV-associated severe LRTD is characterized by presence of lower respiratory signs or an LRTD episode assessed as severe by the investigator (Severe LRTD case definition 1) or presence of an LRTD with need for oxygen supplementation or need for positive airway pressure therapy or need for other types of mechanical ventilation (Severe LRTD case definition 2) and with at least one RSV positive swab detected by RT-PCR.

    Time frame: From Day 15 post first vaccination up to end of season 3 in the NH (assessed approximately over 3 years in NH and 2.5-3 years in SH)

  14. Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated ARI Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses

    Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses is assessed against RSV confirmed A and/or B associated ARI episode. A case of RT-PCR confirmed RSV-associated ARI is characterized by the presence of respiratory symptoms/signs for at least 24 hours OR respiratory symptom/sign + systemic symptom/sign for at least 24 hours with at least one RSV-positive swab detected by RT-PCR.

    Time frame: From Day 15 post first vaccination up to end of season 3 in the NH (assessed approximately over 3 years in NH and 2.5-3 years in SH)

  15. Number of Participants With First Episode of Any ARI or Any LRTD Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses

    Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses is assessed against any ARI and any LRTD.

    Time frame: From Day 15 post first vaccination up to study end (approximately 3 years for NH and 2.5-3 years for SH)

  16. Number of Hospitalizations Due to RSV-confirmed Respiratory Diseases or Due to Complication Related to RSV-confirmed Respiratory Diseases, Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study

    RSV infection was confirmed by RT-PCR.

    Time frame: From Day 15 post-first vaccination up to study end (approximately 3 years for NH and 2.5-3 years for SH)

  17. Number of Hospitalizations Due to Any Respiratory Diseases or Due to a Complication Related to Any Respiratory Diseases, During the RSV Seasons Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study

    A diagnosis of respiratory disease included: acute respiratory infections, other diseases of upper respiratory tract, pneumonia and influenza, chronic obstructive pulmonary disease and allied conditions, pneumoconioses and other lung diseases due to external agents, other diseases of respiratory system.

    Time frame: From Day 15 post-first vaccination up to study end (approximately 3 years for NH and 2.5-3 years for SH)

  18. Number of Complications Related to RSV-confirmed ARI During the RSV Seasons Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study

    RSV infection was confirmed by RT-PCR.

    Time frame: From Day 15 post-first vaccination up to study end (approximately 3 years for NH and 2.5-3 years for SH)

  19. Number of Complications Related to Any ARI During the RSV Seasons Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study

    RSV infection was confirmed by RT-PCR.

    Time frame: From Day 15 post-first vaccination up to study end (approximately 3 years for NH and 2.5-3 years for SH)

  20. Maximum Influenza Patient-Reported Outcome (Flu-PRO) Chest Score for the Participants With RT-PCR-confirmed RSV A and/or B-associated ARI Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses

    For this outcome measure, the Health Related -Quality of life (HR-QOL) score is measured by Flu-PRO questionnaire version 2.0. The Flu-PRO is a 32 items daily diary, which assesses influenza signs across 6 body systems- nose, throat, eyes, chest/respiratory, gastrointestinal and body/systemic. The objective of this outcome measure was to present data only for chest/respiratory system after a single dose and after annual revaccination. The FLU-PRO score was computed as the mean score across questionaire items for chest/respiratory body system, with the scores ranging from 0 (symptom free) to 4 (very severe symptoms).

    Time frame: During the first 7 days from the onset of ARI symptoms (assessed from Day 15 post first vaccination dose until end of study [approximately 3 years in NH and 2.5-3 years in SH])

  21. Least Square Mean Flu-PRO Total Score for the Participants With RT-PCR-confirmed RSV A and/or B-associated ARI Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses

    The Flu-PRO questionnaire version 2.0 is a 32 items daily diary, which assesses influenza signs across 6 body systems- nose, throat, eyes, chest/respiratory, gastrointestinal and body/systemic. The FLU-PRO total score was computed as the mean score across all 32 items of the questionaire for all 6 body systems, with the total scores ranging from 0 (symptom free) to 4 (very severe symptoms).

    Time frame: During the first 7 days from the onset of ARI symptoms (assessed from Day 15 post first vaccination dose until end of study [approximately 3 years in NH and 2.5-3 years in SH])

  22. EuroQol 5-dimension Health Questionnaire (EQ-5D) Utility Score for Participants With RT-PCR-confirmed RSV A and/or B-associated ARI Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses

    The EQ-5D is a general health utility questionnaire with health states, defined through 5 dimensions- mobility, self-care, usual activities, pain/ discomfort and anxiety/ depression. A participant who responds 1 (no problem/no symptom) to all 5 items has a profile "11111" and similarly a participant who responds 3 (the highest level of difficulty or symptom) to all items has a profile "33333". The health states indicated in these 5 dimensions are converted and presented as a single mean index value as recommended by EuroQol group, where values range from 0 (worst) to 1 (full health).

    Time frame: At the ARI visit (assessed from Day 15 post first vaccination dose until end of study- approximately 3 years in NH and 2.5-3 years in SH)

  23. Least Square Mean of Short Form-12 (SF-12) Health Survey for Participants With RT-PCR Confirmed RSV A and/or B-associated ARI Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses

    SF-12 is a health survey with 12 questions, covering 8 domains- physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. Summary scores are computed from these domains for the physical and mental component. The total score of the SF-12 questionnaire is evaluated on a scale from 0 to 100, with a higher score indicating a better perceived health-related quality of life.

    Time frame: At the ARI visit (assessed from one-month post first vaccination dose until end of study- approximately 3 years in NH and 2.5-3 years in SH)

  24. Duration in Days of RT-PCR Confirmed RSV A and/or B ARI and LRTD Episodes

    The duration in days of RT-PCR confirmed RSV A and/or B ARI and LRTD episodes are described.

    Time frame: From Day 15 post first dose to end of Season 1, from 15 days post-second dose administration to end of Season 2, and from start to end of Season 3 [all seasons summing approximately 3 years in NH and 2.5-3 years in SH]

  25. Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 1

    RSV infection was confirmed by RT-PCR, and the symptoms/signs and supportive therapy use associated with RT-PCR confirmed RSV A and/or RSV B ARI episodes were reported. Fever was defined as a temperature ≥38.0 degrees Celsius (°C) by any route.

    Time frame: From Day 15 post-dose 1 administration up to end of season 1 in the SH [a median of approximately 11.5 months (11.6 months in NH and 9.1 months in SH)]

  26. Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 2

    RSV infection was confirmed by RT-PCR, and the symptoms/signs and supportive therapy use associated with RT-PCR confirmed RSV A and/or RSV B ARI episodes were reported. Fever was defined as a temperature ≥38.0 degrees Celsius (°C) by any route.

    Time frame: From Day 15 post-dose 2 administration up to end of Season 2 in SH (a median of approximately 11.9 months [11.9 months in NH and 7.5 months in SH])

  27. Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 3

    RSV infection was confirmed by RT-PCR, and the symptoms/signs and supportive therapy use associated with RT-PCR confirmed RSV A and/or RSV B ARI episodes were reported. Fever was defined as a temperature ≥38.0 degrees Celsius (°C) by any route.

    Time frame: From start of Season 3 up to end of Season 3 in NH (a median of approximately 7 months)

  28. Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 1

    RSV infection was confirmed by RT-PCR, and the symptoms/signs and supportive therapy use associated with RT-PCR confirmed RSV A and/or RSV B LRTD episodes were reported. Fever was defined as a temperature ≥38.0°C by any route.

    Time frame: From Day 15 post-dose 1 administration up to end of season 1 in the SH [a median of approximately 11.5 months (11.6 months in NH and 9.1 months in SH)]

  29. Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 2

    RSV infection was confirmed by RT-PCR, and the symptoms/signs and supportive therapy use associated with RT-PCR confirmed RSV A and/or RSV B LRTD episodes were reported. Fever was defined as a temperature ≥38.0°C by any route.

    Time frame: From Day 15 post-dose 2 administration up to end of Season 2 in SH (a median of approximately 11.9 months [11.9 months in NH and 7.5 months in SH])

  30. Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 3

    RSV infection was confirmed by RT-PCR, and the symptoms/signs and supportive therapy use associated with RT-PCR confirmed RSV A and/or RSV B LRTD episodes were reported. Fever was defined as a temperature ≥38.0°C by any route.

    Time frame: From start of Season 3 up to end of Season 3 in NH (a median of approximately 7 months)

  31. Number of Participants With RT-PCR Confirmed RSV A and/or B ARI and LRTD Episodes According to Severity

    RSV A and/or B ARI and LRTD episodes were assessed as "mild", "moderate" or "severe" by the investigator after the single dose and after annual revaccination. Mild = an ARI/LRTD episode which is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities. Moderate = an ARI/LRTD episode which is sufficiently discomforting to interfere with normal everyday activities. Severe = an ARI/LRTD episode which prevents normal, everyday activities.

    Time frame: Assessed during the study period (approximately 3 years for NH and 2.5-3 years for SH)

  32. RSVPreF3 Specific Immunoglobulin G(IgG) Antibody Concentrations

    The RSVPreF3 IgG antibody concentrations are expressed as geometric mean concentrations (GMCs) in ELISA units per milliliter (EU/mL).

    Time frame: At pre-dose 1 (Day 1), Day 31 post-dose 1, pre-season 2 (approximately 10-17 months post Day 1 in NH; 12-21 months post Day 1 in SH) and pre-season 3 (approximately 24-27 months post Day 1, only in NH)

  33. RSV A Neutralizing Antibody Titers

    The RSV A neutralizing antibody titers are expressed as geometric mean titers (GMTs).

    Time frame: At pre-dose 1 (Day 1), Day 31 post-dose 1, pre-season 2 (approximately 10-17 months post Day 1 in NH; 12-21 months post Day 1 in SH) and pre-season 3 (approximately 24-27 months post Day 1, only in NH)

  34. RSV B Neutralizing Antibody Titers

    RSV B neutralizing antibodies are expressed as GMTs.

    Time frame: At pre-dose 1 (Day 1), Day 31 post-dose 1, pre-season 2 (approximately 10-17 months post Day 1 in NH; 12-21 months post Day 1 in SH) and pre-season 3 (approximately 24-27 months post Day 1, only in NH)

  35. Number of Participants With Any and Grade 3 Solicited Administration Site Adverse Events

    Any solicited event is defined as the occurrence of any solicited adverse event (AE) regardless of intensity grade or relation to study vaccination. Grade 3 = an event which prevented normal, everyday activities. The assessed administration site events include pain, erythema and swelling.

    Time frame: During the 4-day follow up period after first vaccination (Day 1), second vaccination (administered pre-season 2) and after the third vaccination (administered pre-season 3 -only applicable for participants in NH])

  36. Number of Participants With Any and Grade 3 Solicited Systemic Adverse Events

    Any solicited event is defined as the occurrence of any solicited adverse event (AE) regardless of intensity grade or relation to study vaccination. Grade 3 = an event which prevented normal, everyday activities. The assessed solicited systemic events include arthralgia, fatigue, fever, headache and myalgia. Fever is defined as a temperature ≥ 38.0°C by any route. Grade 3 fever is defined as temperature \>39°C by any route.

    Time frame: During the 4-day follow up period after first vaccination (Day 1), second vaccination (administered pre-season 2) and after the third vaccination (administered pre-season 3 -only applicable for participants in NH])

  37. Number of Days With Solicited Administration Site Adverse Events

    Time frame: During the 4-day follow up period after first vaccination (Day 1), second vaccination (administered pre-season 2) and after the third vaccination (administered pre-season 3 -only applicable for participants in NH])

  38. Number of Days With Solicited Systemic Adverse Events

    Time frame: During the 4-day follow up period after first vaccination (Day 1), second vaccination (administered pre-season 2) and after the third vaccination (administered pre-season 3 -only applicable for participants in NH])

  39. Number of Participants With Any Unsolicited AEs

    An unsolicited AE is defined as any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside of the specified period of follow-up for solicited symptoms was reported as an unsolicited AE. Any= occurrence of the event regardless of intensity grade or relation to the study vaccination.

    Time frame: During the 30-day follow up period after first vaccination (Day 1), second vaccination (administered pre-season 2) and after the third vaccination (administered pre-season 3 -only applicable for participants in NH)

  40. Number of Participants With Serious Adverse Events (SAEs)

    An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect in the offspring of a study participant, or in other situations that were considered serious per medical or scientific judgment. Any = occurrence of any SAE regardless of intensity grade or relation to study vaccination.

    Time frame: From the day of the vaccination up to 6 months after each vaccination (first vaccination: at Day 1, second vaccination: at pre-season 2 and the third vaccination: at pre-season 3 -only applicable for participants in NH])

  41. Number of Participants With Potential Immune Mediated Diseases (pIMDs)

    pIMDs aredefined as a subset of Adverse Events of Specific Interest (AESIs) that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Any= occurrence of any pIMD regardless of intensity grade or relation to the study vaccination.

    Time frame: From the day of the vaccination up to 6 months after each vaccination (first vaccination: at Day 1, second vaccination: at pre-season 2 and the third vaccination: at pre-season 3 -only applicable for participants in NH])

  42. Number of Participants With Related SAEs

    Related SAEs that occur throughout the study are assessed. Related SAEs= Any SAE related to investigational vaccine or related to study participation or to a GSK concomitant medication/vaccine as assessed by the investigator.

    Time frame: From Day 1 up to study end (approximately 3 years for NH and 2.5-3 years for SH)

  43. Number of Participants With Fatal SAEs

    Fatal SAEs that occur throughout the study are assessed. Fatal SAEs= Any SAEs leading to deaths.

    Time frame: From Day 1 up to study end (approximately 3 years for NH and 2.5-3 years for SH)

  44. Number of Participants With Related pIMDs

    Related pIMD = pIMD assessed by the investigator as related to the study vaccination.

    Time frame: From Day 1 up to study end (approximately 3 years for NH and 2.5-3 years for SH)

07

Results

Posted Aug 4, 2023

Participant flow

Participant flow — Overall Study
MilestoneRSVPreF3 GroupPlacebo Group
Started1246912503
Rsv 1 dose62260
Rsv annual62430
Completed93659361
Not completed31043142
Withdrew: Adverse event442441
Withdrew: Lost to follow-up448465
Withdrew: Consent withdrawal, not due to a (s)ae17151726
Withdrew: Migrated/moved from the study area201184
Withdrew: Other298326

Outcome measures

PrimaryNumber of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated Lower Respiratory Tract Disease (LRTD) During the First Season Following a Single Dose of the RSVPreF3 OA Vaccine

First episode of Reverse Transcriptase-Polymerase Chain Reaction (RT-PCR)-confirmed RSV A and/or RSV B- associated LRTD during the first season was assessed. The case definition for RSV-confirmed LRTD is as follows: Presence of at least one RSV-positive swab detected by RT-PCR.

Time frame:
From Day 15 post-vaccination up to end of season 1 in the Northern Hemisphere (NH) [a median of approximately 6.7 months (6.9 months in NH and 3.5 months in Southern Hemisphere [SH])]
Reported as:
Count of participants · Participants
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated Lower Respiratory Tract Disease (LRTD) During the First Season Following a Single Dose of the RSVPreF3 OA Vaccine
ParticipantsRSVPreF3 GroupPlacebo Group
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated Lower Respiratory Tract Disease (LRTD) During the First Season Following a Single Dose of the RSVPreF3 OA Vaccine740
Statistical analysis
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 82.58 · 96.95% CI 57.89 to 94.08VE in terms of occurrence of RSV-confirmed LRTD was evaluated using the conditional exact binomial method based on the Poisson model
SecondaryNumber of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD Over Several Seasons Following a Single Dose of the RSVPreF3 OA Vaccine

Efficacy of a single dose of the RSVPreF3 OA vaccine was assessed against RSV A and/or B confirmed LRTD over several seasons according to the case definition.

Time frame:
From Day 15 post first vaccination up to end of season 2 and up to end of season 3 in the Northern Hemisphere [NH] (assessed approximately over 2 and 3 years in NH)
Reported as:
Count of participants · Participants
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD Over Several Seasons Following a Single Dose of the RSVPreF3 OA Vaccine
ParticipantsRSVPreF3 GroupPlacebo Group
Season 2 (NH)30139
Season 3 (NH)48215
Statistical analysis
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 62.91 · 97.5% CI 46.74 to 74.79VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (%) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 67.18 · 97.5% CI 48.19 to 80.04VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (%) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
SecondaryNumber of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD Over Several Seasons Following Annual Revaccination Doses of the RSVPreF3 OA Vaccine

Efficacy of annual revaccination doses of the RSVPreF3 OA vaccine was assessed against RSV A and/or B confirmed LRTD over several seasons according to the case definition.

Time frame:
From Day 15 post first vaccination up to end of season 2 and up to end of season 3 in the NH (assessed approximately over 2 and 3 years in NH)
Reported as:
Count of participants · Participants
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD Over Several Seasons Following Annual Revaccination Doses of the RSVPreF3 OA Vaccine
ParticipantsRSVPreF3 GroupPlacebo Group
Season 2 (NH)30139
Season 3 (NH)38192
Statistical analysis
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 67.76 · 97.5% CI 51.82 to 79.11VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (%) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 67.12 · 97.5% CI 48.09 to 80.00VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (%) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
SecondaryNumber of Participants With First Episode of RT-PCR Confirmed RSV Subtype A and Subtype B LRTD Over 3 Seasons Following a Single Dose of the RSVPreF3 OA Vaccine

Efficacy of a single dose of the RSVPreF3 OA vaccine was assessed against LRTD episode caused by RSV A and B subtype over 3 seasons according to the case definition.

Time frame:
From Day 15 post first vaccination up to end of season 3 in the NH (assessed approximately over 3 years in NH, and 2.5-3 years in SH)
Reported as:
Count of participants · Participants
Number of Participants With First Episode of RT-PCR Confirmed RSV Subtype A and Subtype B LRTD Over 3 Seasons Following a Single Dose of the RSVPreF3 OA Vaccine
ParticipantsRSVPreF3 GroupPlacebo Group
RT-PCR-confirmed RSV-A LRTD1480
RT-PCR-confirmed RSV-B LRTD34135
Statistical analysis
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 69.83 · 97.5% CI 42.18 to 85.72VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 58.57 · 97.5% CI 35.90 to 74.11VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
SecondaryNumber of Participants With First Episode of RT-PCR Confirmed RSV Subtype A and Subtype B LRTD Over 3 Seasons Following a Single Dose of the RSVPreF3 OA Vaccine and Following 1 Annual Revaccination Dose

Efficacy of a single dose and 1 annual revaccination dose of the RSVPreF3 OA vaccine was assessed against LRTD episode caused by RSV A and B subtype over 3 seasons according to the case definition.

Time frame:
From Day 15 post first vaccination up to end of season 3 in the NH (assessed approximately over 3 years in NH, and 2.5-3 years in SH)
Reported as:
Count of participants · Participants
Number of Participants With First Episode of RT-PCR Confirmed RSV Subtype A and Subtype B LRTD Over 3 Seasons Following a Single Dose of the RSVPreF3 OA Vaccine and Following 1 Annual Revaccination Dose
ParticipantsRSVPreF3 GroupPlacebo Group
RT-PCR-confirmed RSV-A LRTD1765
RT-PCR-confirmed RSV-B LRTD21127
Statistical analysis
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 55.12 · 97.5% CI 16.52 to 77.52VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 73.58 · 97.5% CI 55.10 to 85.40VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
SecondaryNumber of Participants With First Episode of RT-PCR Confirmed LRTD Caused by Human Metapneumovirus (hMPV) up to the End of Season 1 Following a Single Dose of the RSVPreF3 OA Vaccine
Time frame:
From Day 15 post-vaccination up to end of season 1 in the SH [a median of approximately 11.5 months (11.6 months in NH and 9.1 months in SH)]
Reported as:
Count of participants · Participants
Number of Participants With First Episode of RT-PCR Confirmed LRTD Caused by Human Metapneumovirus (hMPV) up to the End of Season 1 Following a Single Dose of the RSVPreF3 OA Vaccine
ParticipantsRSVPreF3 GroupPlacebo Group
Number of Participants With First Episode of RT-PCR Confirmed LRTD Caused by Human Metapneumovirus (hMPV) up to the End of Season 1 Following a Single Dose of the RSVPreF3 OA Vaccine5365
Statistical analysis
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 18.41 · 95% CI -19.10 to 44.33VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season)
SecondaryNumber of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD, by Age Categories Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses

Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses was assessed against RSV A and/or B confirmed LRTD episode according to the case definition, in the following age categories: greater than or equal to (≥) 65 years of age (YOA), ≥70 YOA and ≥80 YOA.

Time frame:
From Day 15 post first vaccination up to end of season 3 in the NH (assessed approximately over 3 years in NH and 2.5-3 years in SH)
Reported as:
Count of participants · Participants
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD, by Age Categories Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
ParticipantsRSVPreF3 GroupPlacebo Group
RT-PCR-confirmed RSV LRTD (Single dose), >=65 YOA38156
RT-PCR-confirmed RSV LRTD (Single dose), >=70 YOA2098
RT-PCR-confirmed RSV LRTD (Single dose), >=80 YOA,513
RT-PCR-confirmed RSV LRTD (Annual revaccination), >=65 YOA28137
RT-PCR-confirmed RSV LRTD (Annual revaccination), >=70 YOA1987
RT-PCR-confirmed RSV LRTD (Annual revaccination), >=80 YOA512
Statistical analysis
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 58.78 · 95% CI 40.73 to 71.96VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 65.98 · 95% CI 44.32 to 80.16VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 36.24 · 95% CI -93.99 to 82.47VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 66.56 · 95% CI 49.33 to 78.64VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 64.25 · 95% CI 40.49 to 79.55VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 32.81 · 95% CI -108.42 to 81.73VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by region and season).
SecondaryNumber of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by RSV Season Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses

Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses was assessed against RSV A and/or B confirmed LRTD episode according to the case definition, by RSV season as follows: VE after each season includes the first occurrence of episodes reported from Day 15 post vaccination at first season, and for the next seasons, excluding analysis of participants who already reported a case in the previous season. The RSV season may be extended based on epidemiology data.

Time frame:
From Day 15 post first dose or start of the RSV season to the first occurrence of RSV-confirmed LRTD at each RSV season (assessed approximately over 7 months at each season [Seasons 1 and 2 in SH, Seasons 1, 2 and 3 in NH])
Reported as:
Count of participants · Participants
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by RSV Season Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
ParticipantsRSVPreF3 GroupPlacebo GroupRSV_1_dose GroupRSV_annual Group
RT-PCR-confirmed RSV LRTD, Season 1736——
RT-PCR-confirmed RSV LRTD, Season 2 (Single dose)—9819—
RT-PCR-confirmed RSV LRTD, Season 2 (Annual revaccination)—98—22
RT-PCR-confirmed RSV LRTD, Season 3 (Single dose)—6016—
RT-PCR-confirmed RSV LRTD, Season 3 (Annual revaccination)—37—6
Statistical analysis
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 80.64 · 95% CI 55.90 to 92.73VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, and region).
  • Placebo Group vs RSV_1_dose Group · Poisson regression method · Ve: 61.39 · 95% CI 36.44 to 77.70VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, and region).
  • Placebo Group vs RSV_1_dose Group · Poisson regression method · Ve: 47.15 · 95% CI 7.06 to 71.59VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, and region).
  • Placebo Group vs RSV_annual Group · Poisson regression method · Ve: 54.92 · 95% CI 27.85 to 72.98VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, and region).
  • Placebo Group vs RSV_annual Group · Poisson regression method · Ve: 67.51 · 95% CI 22.35 to 88.79VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, and region).
SecondaryNumber of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by Year Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses

Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses was assessed against RSV A and/or B confirmed LRTD episode according to the case definition, by years after vaccination as follows: VE at each year includes the first occurrence of episodes reported from Day 14 post vaccination at first year, and for the next years, excluding analysis of participants who already reported a case in the previous year.

Time frame:
From Day 15 post first dose and each revaccination dose up to next dose or end of study (assessed approximately over a year after each vaccination [at Year 1, Year 2 and Year 3])
Reported as:
Count of participants · Participants
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by Year Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
ParticipantsRSVPreF3 GroupPlacebo GroupRSV_1_dose GroupRSV_annual Group
RT-PCR-confirmed RSV LRTD, Year 11047——
RT-PCR-confirmed RSV LRTD, Year 2 (Single dose)—10622—
RT-PCR-confirmed RSV LRTD, Year 2 (Annual revaccination)—106—22
RT-PCR-confirmed RSV LRTD, Year 3 (Single dose)—6116—
RT-PCR-confirmed RSV LRTD, Year 3 (Annual revaccination)—38—6
Statistical analysis
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 78.86 · 95% CI 57.62 to 90.48VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, and region).
  • Placebo Group vs RSV_1_dose Group · Poisson regression method · Ve: 58.59 · 95% CI 34.00 to 75.10VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, and region).
  • Placebo Group vs RSV_1_dose Group · Poisson regression method · Ve: 47.91 · 95% CI 8.51 to 71.97VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, and region).
  • Placebo Group vs RSV_annual Group · Poisson regression method · Ve: 58.33 · 95% CI 33.59 to 74.94VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, and region).
  • Placebo Group vs RSV_annual Group · Poisson regression method · Ve: 68.40 · 95% CI 24.64 to 89.08VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, and region).
SecondaryNumber of Participants With First Episode of RT-PCR Confirmed RSV A and /or B Associated LRTD, Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
Time frame:
From Day 15 post first dose to the first occurrence of RSV LRTD (assessed approximately over 3 years in the NH and 2.5-3 years in SH)
Reported as:
Count of participants · Participants
Number of Participants With First Episode of RT-PCR Confirmed RSV A and /or B Associated LRTD, Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
ParticipantsRSVPreF3 GroupPlacebo Group
Season 11047
Season 2 (Single dose)32154
Season 2 (Annual revaccination)32154
Season 3 (NH) (Single dose)48215
Season 3 (NH) (Annual revaccination)38192
Statistical analysis
  • RSVPreF3 Group vs Placebo Group · Regression, Cox · Ve: 78.75 · 95% CI 57.95 to 89.26VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (%) = Vaccine Efficacy (Piecewise Cox model with time-varying efficacy - adjusted by age and region).
  • RSVPreF3 Group vs Placebo Group · Regression, Cox · Ve: 67.63 · 95% CI 52.47 to 77.95VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (%) = Vaccine Efficacy (Piecewise Cox model with time-varying efficacy - adjusted by age and region).
  • RSVPreF3 Group vs Placebo Group · Regression, Cox · Ve: 62.87 · 95% CI 46.76 to 74.11VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (%) = Vaccine Efficacy (Piecewise Cox model with time-varying efficacy - adjusted by age and region).
  • RSVPreF3 Group vs Placebo Group · Regression, Cox · Ve: 67.49 · 95% CI 52.27 to 77.86VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (%) = Vaccine Efficacy (Piecewise Cox model with time-varying efficacy - adjusted by age and region).
  • RSVPreF3 Group vs Placebo Group · Regression, Cox · Ve: 67.66 · 95% CI 51.71 to 78.34VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (%) = Vaccine Efficacy (Piecewise Cox model with time-varying efficacy - adjusted by age and region).
SecondaryNumber of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by Baseline Comorbidities Using Charlson Comorbidity Index Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses

Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses is assessed against RSV A and/or B associated LRTD episode by baseline comorbidities using Charlson Comorbidity Index. Low/medium Risk = Participants with co-morbidity score at baseline less than or equal to 3 (Charlson Index); High Risk = Participants with co-morbidity score at baseline greater than 3 (Charlson Index).

Time frame:
From Day 15 post first vaccination up to end of season 3 in the NH (assessed approximately over 3 years in NH and 2.5-3 years in SH)
Reported as:
Count of participants · Participants
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by Baseline Comorbidities Using Charlson Comorbidity Index Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
ParticipantsRSVPreF3 GroupPlacebo Group
RT-PCR-confirmed RSV LRTD (Single dose), Low/Medium risk24119
RT-PCR-confirmed RSV LRTD (Single dose), High risk2496
RT-PCR-confirmed RSV LRTD (Annual revaccination), Low/Medium risk18108
RT-PCR-confirmed RSV LRTD (Annual revaccination), High risk2084
Statistical analysis
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 66.49 · 95% CI 47.54 to 79.40VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 58.88 · 95% CI 34.81 to 74.98VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 72.55 · 95% CI 54.34 to 84.37VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 61.99 · 95% CI 37.17 to 78.01VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
SecondaryNumber of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by Baseline Comorbidities According to Comorbidities of Interest Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses

Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses is assessed against RSV A and/or B associated LRTD episode by baseline comorbidities of interest divided into 2: cardiorespiratory conditions such as chronic obstructive pulmonary disease (COPD), asthma, any chronic respiratory or pulmonary disease, and endocrinometabolic conditions such as diabetes mellitus type 1 or 2, chronic heart failure and advanced liver or renal disease.

Time frame:
From Day 15 post first vaccination up to end of season 3 in the NH (assessed approximately over 3 years in NH and 2.5-3 years in SH)
Reported as:
Count of participants · Participants
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by Baseline Comorbidities According to Comorbidities of Interest Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
ParticipantsRSVPreF3 GroupPlacebo Group
Confirmed RSV LRTD (Single dose), No pre-existing comorbidity of interest2399
Confirmed RSV LRTD (Single dose), At least 1 pre-existing comorbidity of interest25116
Confirmed RSV LRTD (Single dose), At least 1 pre-existing Cardiorespiratory condition1785
Confirmed RSV LRTD (Single dose), At least 1 pre-existing Endocrinometabolic condition1255
Confirmed RSV LRTD (Annual revaccination), No pre-existing comorbidity of interest2091
Confirmed RSV LRTD (Annual revaccination), At least 1 pre-existing comorbidity of interest18101
Confirmed RSV LRTD (Annual revaccination), At least 1 pre-existing Cardiorespiratory condition1173
Confirmed RSV LRTD (Annual revaccination), At least 1 pre-existing Endocrinometabolic condition949
Statistical analysis
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 61.48 · 95% CI 38.62 to 76.74VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 64.73 · 95% CI 45.10 to 78.14VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 68.14 · 95% CI 45.71 to 82.33VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 63.88 · 95% CI 31.35 to 82.48VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 64.16 · 95% CI 41.08 to 79.17VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 71.19 · 95% CI 51.92 to 83.65VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 75.94 · 95% CI 54.11 to 88.54VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 69.85 · 95% CI 37.51 to 87.05VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
SecondaryNumber of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by Baseline Frailty Status Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses

Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses is assessed against RSV A and /or B associated LRTD episode according to the case definition, by baseline frailty status of frail, pre-frail and fit. Frail = Participants with a walking speed of less than (\<) 0.4 meters per second (m/s) or who were not able to perform the test; Pre-Frail = Participants with a walking speed between 0.4-0.99 m/s; Fit = Participants with a walking speed of ≥1 m/s.

Time frame:
From Day 15 post first vaccination up to end of season 3 in the NH (assessed approximately over 3 years in NH and 2.5-3 years in SH)
Reported as:
Count of participants · Participants
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated LRTD by Baseline Frailty Status Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
ParticipantsRSVPreF3 GroupPlacebo Group
RT-PCR-confirmed RSV LRTD (Single dose), Frail21
RT-PCR-confirmed RSV LRTD (Single dose), Pre-Frail1267
RT-PCR-confirmed RSV LRTD (Single dose), Fit34145
RT-PCR-confirmed RSV LRTD (Annual revaccination), Frail11
RT-PCR-confirmed RSV LRTD (Annual revaccination), Pre-Frail1063
RT-PCR-confirmed RSV LRTD (Annual revaccination), Fit27126
Statistical analysis
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: -153.57 · 95% CI -16322.97 to 88.00VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 70.07 · 95% CI 43.89 to 85.33VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 61.04 · 95% CI 42.89 to 74.08VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 13.62 · 95% CI -6751.38 to 98.91VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 74.32 · 95% CI 49.33 to 88.31VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 64.79 · 95% CI 46.10 to 77.75VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
SecondaryNumber of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated Severe LRTD Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses

Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses is assessed against RSV A and/or B associated severe LRTD episode. Case definition for RSV-confirmed severe LRTD: An RT-PCR confirmed case of RSV-associated severe LRTD is characterized by presence of lower respiratory signs or an LRTD episode assessed as severe by the investigator (Severe LRTD case definition 1) or presence of an LRTD with need for oxygen supplementation or need for positive airway pressure therapy or need for other types of mechanical ventilation (Severe LRTD case definition 2) and with at least one RSV positive swab detected by RT-PCR.

Time frame:
From Day 15 post first vaccination up to end of season 3 in the NH (assessed approximately over 3 years in NH and 2.5-3 years in SH)
Reported as:
Count of participants · Participants
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated Severe LRTD Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
ParticipantsRSVPreF3 GroupPlacebo Group
RT-PCR-confirmed RSV severe LRTD (Single dose), Any1575
RT-PCR-confirmed RSV severe LRTD (Single dose), Definition 1: Clinical symptomology1575
RT-PCR-confirmed RSV severe LRTD (Single dose), Definition 2: Supportive therapy27
RT-PCR-confirmed RSV severe LRTD (Annual revaccination), Any967
RT-PCR-confirmed RSV severe LRTD (Annual revaccination), Definition 1: Clinical symptomology967
RT-PCR-confirmed RSV severe LRTD (Annual revaccination), Definition 2: Supportive therapy06
Statistical analysis
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 67.38 · 95% CI 42.43 to 82.68VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 67.38 · 95% CI 42.43 to 82.68VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 59.16 · 95% CI -119.60 to 95.93VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 78.80 · 95% CI 57.05 to 90.75VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 78.80 · 95% CI 57.05 to 90.75VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 100.00 · 95% CI 20.27 to 100.00VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
SecondaryNumber of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated ARI Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses

Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses is assessed against RSV confirmed A and/or B associated ARI episode. A case of RT-PCR confirmed RSV-associated ARI is characterized by the presence of respiratory symptoms/signs for at least 24 hours OR respiratory symptom/sign + systemic symptom/sign for at least 24 hours with at least one RSV-positive swab detected by RT-PCR.

Time frame:
From Day 15 post first vaccination up to end of season 3 in the NH (assessed approximately over 3 years in NH and 2.5-3 years in SH)
Reported as:
Count of participants · Participants
Number of Participants With First Episode of RT-PCR Confirmed RSV A and/or B Associated ARI Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
ParticipantsRSVPreF3 GroupPlacebo Group
RT-PCR-confirmed RSV ARI (Single dose)131428
RT-PCR-confirmed RSV ARI (Annual revaccination)103385
Statistical analysis
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 51.13 · 95% CI 40.31 to 60.21VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 58.44 · 95% CI 48.10 to 66.96VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
SecondaryNumber of Participants With First Episode of Any ARI or Any LRTD Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses

Efficacy of a single dose of the RSVPreF3 OA vaccine and annual revaccination doses is assessed against any ARI and any LRTD.

Time frame:
From Day 15 post first vaccination up to study end (approximately 3 years for NH and 2.5-3 years for SH)
Reported as:
Count of participants · Participants
Number of Participants With First Episode of Any ARI or Any LRTD Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
ParticipantsRSVPreF3 GroupPlacebo Group
Any ARI (Single dose)48586096
Any ARI (Annual revaccination)47315914
Any LRTD (Single dose)124503352
Any LRTD (Annual revaccination)23083210
Statistical analysis
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 2.33 · 95% CI -1.47 to 5.99VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 3.32 · 95% CI -0.50 to 6.98VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 3.68 · 95% CI -1.55 to 8.63VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 6.99 · 95% CI 1.81 to 11.90VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
SecondaryNumber of Hospitalizations Due to RSV-confirmed Respiratory Diseases or Due to Complication Related to RSV-confirmed Respiratory Diseases, Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study

RSV infection was confirmed by RT-PCR.

Time frame:
From Day 15 post-first vaccination up to study end (approximately 3 years for NH and 2.5-3 years for SH)
Reported as:
Count of participants · Participants
Number of Hospitalizations Due to RSV-confirmed Respiratory Diseases or Due to Complication Related to RSV-confirmed Respiratory Diseases, Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study
ParticipantsRSVPreF3 GroupPlacebo Group
RSV respiratory disease (Single dose), during season24
RSV respiratory disease or related complication (Single dose), during season24
RSV respiratory disease (Annual revaccination),during season04
RSV respiratory disease or related complication (Annual revaccination), during season04
RSV respiratory disease (Single dose), up to end of study26
RSV respiratory disease or related complication (Single dose), up to end of study26
RSV respiratory disease (Annual revaccination), up to end of study06
RSV respiratory disease or related complication (Annual revaccination), up to end of study06
Statistical analysis
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 50.37 · 95% CI -184.45 to 95.19VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 50.37 · 95% CI -184.45 to 95.19VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 100.00 · 95% CI 11.56 to 100.00VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 100.00 · 95% CI 11.56 to 100.00VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 22.14 · 95% CI -457.67 to 93.12VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 22.14 · 95% CI -457.67 to 93.12VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 100.00 · 95% CI -54.53 to 100.00VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 100.00 · 95% CI -54.53 to 100.00VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
SecondaryNumber of Hospitalizations Due to Any Respiratory Diseases or Due to a Complication Related to Any Respiratory Diseases, During the RSV Seasons Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study

A diagnosis of respiratory disease included: acute respiratory infections, other diseases of upper respiratory tract, pneumonia and influenza, chronic obstructive pulmonary disease and allied conditions, pneumoconioses and other lung diseases due to external agents, other diseases of respiratory system.

Time frame:
From Day 15 post-first vaccination up to study end (approximately 3 years for NH and 2.5-3 years for SH)
Reported as:
Count of participants · Participants
Number of Hospitalizations Due to Any Respiratory Diseases or Due to a Complication Related to Any Respiratory Diseases, During the RSV Seasons Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study
ParticipantsRSVPreF3 GroupPlacebo Group
Any respiratory disease (Single dose), during seasons121174
Any respiratory disease or related complication (Single dose), during seasons131180
Any respiratory disease (Annual revaccination), during seasons114163
Any respiratory disease or related complication (Annual revaccination), during seasons119169
Any respiratory disease (Single dose), up to end of study167221
Any respiratory disease or related complication (Single dose), up to end of study179230
Any respiratory disease (Annual revaccination), up to end of study163208
Any respiratory disease or related complication (Annual revaccination), up to end of study171217
Statistical analysis
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: -1.81 · 95% CI -25.43 to 17.49VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: -4.72 · 95% CI -28.26 to 14.61VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: -3.61 · 95% CI -28.20 to 16.38VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: -3.59 · 95% CI -27.55 to 15.98VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 2.98 · 95% CI -23.52 to 23.99VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: -1.71 · 95% CI -28.56 to 19.70VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 4.80 · 95% CI -22.14 to 26.00VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 4.64 · 95% CI -21.73 to 25.48VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
SecondaryNumber of Complications Related to RSV-confirmed ARI During the RSV Seasons Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study

RSV infection was confirmed by RT-PCR.

Time frame:
From Day 15 post-first vaccination up to study end (approximately 3 years for NH and 2.5-3 years for SH)
Reported as:
Count of participants · Participants
Number of Complications Related to RSV-confirmed ARI During the RSV Seasons Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study
ParticipantsRSVPreF3 GroupPlacebo Group
Related to RT-PCR-confirmed RSV ARI (Single dose), up to end of study1250
Related to RT-PCR-confirmed RSV ARI (Annual revaccination), up to end of study1146
Related to RT-PCR-confirmed RSV ARI (Single dose), during season943
Related to RT-PCR-confirmed RSV ARI (Annual revaccination), during season939
Statistical analysis
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 62.94 · 95% CI 28.91 to 82.15VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 63.80 · 95% CI 28.50 to 83.20VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 65.69 · 95% CI 28.56 to 85.47VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 62.87 · 95% CI 21.45 to 84.29VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
SecondaryNumber of Complications Related to Any ARI During the RSV Seasons Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study

RSV infection was confirmed by RT-PCR.

Time frame:
From Day 15 post-first vaccination up to study end (approximately 3 years for NH and 2.5-3 years for SH)
Reported as:
Count of participants · Participants
Number of Complications Related to Any ARI During the RSV Seasons Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses up to End of Study
ParticipantsRSVPreF3 GroupPlacebo Group
Complications related to any ARI (Single dose), during season438695
Complications related to any ARI (Annual revaccination), during season417660
Complications related to any ARI (Single dose), up to end of study620863
Complications related to any ARI (Annual revaccination), up to end of study579823
Statistical analysis
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 2.59 · 95% CI -8.29 to 12.42VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 6.70 · 95% CI -4.05 to 16.39VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 10.95 · 95% CI -0.68 to 21.31VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
  • RSVPreF3 Group vs Placebo Group · Poisson regression method · Ve: 12.12 · 95% CI 0.32 to 22.58VE is defined as 1 minus the relative risk (RR). RR=the ratio of the incidence rates of RSVPreF3 Group over Placebo Group. VE (% ) = Vaccine Efficacy (Poisson method - adjusted by age, region and season).
SecondaryMaximum Influenza Patient-Reported Outcome (Flu-PRO) Chest Score for the Participants With RT-PCR-confirmed RSV A and/or B-associated ARI Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses

For this outcome measure, the Health Related -Quality of life (HR-QOL) score is measured by Flu-PRO questionnaire version 2.0. The Flu-PRO is a 32 items daily diary, which assesses influenza signs across 6 body systems- nose, throat, eyes, chest/respiratory, gastrointestinal and body/systemic. The objective of this outcome measure was to present data only for chest/respiratory system after a single dose and after annual revaccination. The FLU-PRO score was computed as the mean score across questionaire items for chest/respiratory body system, with the scores ranging from 0 (symptom free) to 4 (very severe symptoms).

Time frame:
During the first 7 days from the onset of ARI symptoms (assessed from Day 15 post first vaccination dose until end of study [approximately 3 years in NH and 2.5-3 years in SH])
Reported as:
Mean · Scores on a scale
Maximum Influenza Patient-Reported Outcome (Flu-PRO) Chest Score for the Participants With RT-PCR-confirmed RSV A and/or B-associated ARI Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
Scores on a scaleRSVPreF3 GroupPlacebo Group
Chest / Respiratory (Single dose)1.60 ± 0.891.97 ± 0.88
Chest / Respiratory (Annual revaccination)1.50 ± 0.871.96 ± 0.89
SecondaryLeast Square Mean Flu-PRO Total Score for the Participants With RT-PCR-confirmed RSV A and/or B-associated ARI Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses

The Flu-PRO questionnaire version 2.0 is a 32 items daily diary, which assesses influenza signs across 6 body systems- nose, throat, eyes, chest/respiratory, gastrointestinal and body/systemic. The FLU-PRO total score was computed as the mean score across all 32 items of the questionaire for all 6 body systems, with the total scores ranging from 0 (symptom free) to 4 (very severe symptoms).

Time frame:
During the first 7 days from the onset of ARI symptoms (assessed from Day 15 post first vaccination dose until end of study [approximately 3 years in NH and 2.5-3 years in SH])
Reported as:
Least squares mean · Scores on a scale
Least Square Mean Flu-PRO Total Score for the Participants With RT-PCR-confirmed RSV A and/or B-associated ARI Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
Scores on a scaleRSVPreF3 GroupPlacebo Group
Day 1 to Day 7 (Single dose)0.85 ± 0.070.92 ± 0.06
Day 1 to Day 7 (Annual revaccination)0.81 ± 0.070.90 ± 0.06
SecondaryEuroQol 5-dimension Health Questionnaire (EQ-5D) Utility Score for Participants With RT-PCR-confirmed RSV A and/or B-associated ARI Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses

The EQ-5D is a general health utility questionnaire with health states, defined through 5 dimensions- mobility, self-care, usual activities, pain/ discomfort and anxiety/ depression. A participant who responds 1 (no problem/no symptom) to all 5 items has a profile "11111" and similarly a participant who responds 3 (the highest level of difficulty or symptom) to all items has a profile "33333". The health states indicated in these 5 dimensions are converted and presented as a single mean index value as recommended by EuroQol group, where values range from 0 (worst) to 1 (full health).

Time frame:
At the ARI visit (assessed from Day 15 post first vaccination dose until end of study- approximately 3 years in NH and 2.5-3 years in SH)
Reported as:
Least squares mean · Scores on a scale
EuroQol 5-dimension Health Questionnaire (EQ-5D) Utility Score for Participants With RT-PCR-confirmed RSV A and/or B-associated ARI Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
Scores on a scaleRSVPreF3 GroupPlacebo Group
At ARI visit (Single dose)0.8164 ± 0.02580.7886 ± 0.0197
At ARI visit (Annual revaccination)0.8377 ± 0.02590.7966 ± 0.0197
SecondaryLeast Square Mean of Short Form-12 (SF-12) Health Survey for Participants With RT-PCR Confirmed RSV A and/or B-associated ARI Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses

SF-12 is a health survey with 12 questions, covering 8 domains- physical functioning, role physical, bodily pain, general health, vitality, social functioning, role emotional and mental health. Summary scores are computed from these domains for the physical and mental component. The total score of the SF-12 questionnaire is evaluated on a scale from 0 to 100, with a higher score indicating a better perceived health-related quality of life.

Time frame:
At the ARI visit (assessed from one-month post first vaccination dose until end of study- approximately 3 years in NH and 2.5-3 years in SH)
Reported as:
Least squares mean · Scores on a scale
Least Square Mean of Short Form-12 (SF-12) Health Survey for Participants With RT-PCR Confirmed RSV A and/or B-associated ARI Following a Single Dose of the RSVPreF3 OA Vaccine and Following Annual Revaccination Doses
Scores on a scaleRSVPreF3 GroupPlacebo Group
At ARI visit (Single dose)59.43 ± 4.0757.51 ± 3.15
At ARI visit (Annual revaccination)63.65 ± 4.1559.02 ± 3.18
SecondaryDuration in Days of RT-PCR Confirmed RSV A and/or B ARI and LRTD Episodes

The duration in days of RT-PCR confirmed RSV A and/or B ARI and LRTD episodes are described.

Time frame:
From Day 15 post first dose to end of Season 1, from 15 days post-second dose administration to end of Season 2, and from start to end of Season 3 [all seasons summing approximately 3 years in NH and 2.5-3 years in SH]
Reported as:
Median · Days
Duration in Days of RT-PCR Confirmed RSV A and/or B ARI and LRTD Episodes
DaysRSVPreF3 GroupPlacebo GroupRSV_1_dose GroupRSV_annual Group
RT-PCR-confirmed RSV ARI, Season 112.0 (8.0 to 19.0)15.0 (11.0 to 22.0)——
RT-PCR-confirmed RSV LRTD, Season 115.5 (8.0 to 19.0)20.0 (15.0 to 27.0)——
RT-PCR-confirmed RSV ARI, Season 2—16.0 (12.0 to 24.0)14.0 (10.0 to 23.0)13.0 (9.0 to 18.0)
RT-PCR-confirmed RSV LRTD, Season 2—16.0 (13.0 to 24.0)17.0 (10.0 to 28.0)14.0 (9.0 to 23.0)
RT-PCR-confirmed RSV ARI, Season 3—16.0 (14.0 to 22.0)16.0 (13.0 to 24.0)10.0 (7.0 to 21.0)
RT-PCR-confirmed RSV LRTD, Season 3—17.5 (14.5 to 26.0)16.5 (15.0 to 24.5)12.0 (7.0 to 21.0)
SecondaryNumber of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 1

RSV infection was confirmed by RT-PCR, and the symptoms/signs and supportive therapy use associated with RT-PCR confirmed RSV A and/or RSV B ARI episodes were reported. Fever was defined as a temperature ≥38.0 degrees Celsius (°C) by any route.

Time frame:
From Day 15 post-dose 1 administration up to end of season 1 in the SH [a median of approximately 11.5 months (11.6 months in NH and 9.1 months in SH)]
Reported as:
Count of participants · Participants
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 1
ParticipantsRSVPreF3 GroupPlacebo Group
Nasal Congestion2883
Rhinorrhea3293
Sore Throat2676
Cough (new or increased)36101
Sputum (new or increased)2075
Shortness of breath or dyspnea (new or increased)735
Wheezing (new or increased)525
Crackles16
Rhonchi113
Respiratory rate ≥20 breaths/minute311
Low or decreased oxygen saturation19
Fever28
Feverishness824
Fatigue2267
Body aches1240
Headache2055
Decreased appetite1342
Need for oxygen supplementation04
Need for positive airway pressure therapy00
Need of other types of mechanical ventilation00
Other symptoms or signs722
SecondaryNumber of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 2

RSV infection was confirmed by RT-PCR, and the symptoms/signs and supportive therapy use associated with RT-PCR confirmed RSV A and/or RSV B ARI episodes were reported. Fever was defined as a temperature ≥38.0 degrees Celsius (°C) by any route.

Time frame:
From Day 15 post-dose 2 administration up to end of Season 2 in SH (a median of approximately 11.9 months [11.9 months in NH and 7.5 months in SH])
Reported as:
Count of participants · Participants
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 2
ParticipantsPlacebo GroupRSV_1_dose GroupRSV_annual Group
Nasal Congestion1624331
Rhinorrhea1865239
Sore Throat1474333
Cough (new or increased)2015541
Sputum (new or increased)1503929
Shortness of breath or dyspnea (new or increased)791719
Wheezing (new or increased)561510
Crackles1923
Rhonchi3287
Respiratory rate ≥20 breaths/minute2150
Low or decreased oxygen saturation814
Fever2157
Feverishness641315
Fatigue1453433
Body aches912724
Headache1243628
Decreased appetite852018
Need for oxygen supplementation110
Need for positive airway pressure therapy010
Need of other types of mechanical ventilation000
Other symptoms or signs481214
SecondaryNumber of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 3

RSV infection was confirmed by RT-PCR, and the symptoms/signs and supportive therapy use associated with RT-PCR confirmed RSV A and/or RSV B ARI episodes were reported. Fever was defined as a temperature ≥38.0 degrees Celsius (°C) by any route.

Time frame:
From start of Season 3 up to end of Season 3 in NH (a median of approximately 7 months)
Reported as:
Count of participants · Participants
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B ARI Episodes During Season 3
ParticipantsPlacebo GroupRSV_1_dose GroupRSV_annual Group
Nasal Congestion1012515
Rhinorrhea982617
Sore Throat761714
Cough (new or increased)1112718
Sputum (new or increased)862310
Shortness of breath or dyspnea (new or increased)42105
Wheezing (new or increased)3263
Crackles1020
Rhonchi1682
Respiratory rate ≥20 breaths/minute930
Low or decreased oxygen saturation1113
Fever1020
Feverishness32146
Fatigue852115
Body aches561610
Headache661612
Decreased appetite521312
Need for oxygen supplementation010
Need for positive airway pressure therapy000
Need of other types of mechanical ventilation000
Other symptoms or signs3569
SecondaryNumber of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 1

RSV infection was confirmed by RT-PCR, and the symptoms/signs and supportive therapy use associated with RT-PCR confirmed RSV A and/or RSV B LRTD episodes were reported. Fever was defined as a temperature ≥38.0°C by any route.

Time frame:
From Day 15 post-dose 1 administration up to end of season 1 in the SH [a median of approximately 11.5 months (11.6 months in NH and 9.1 months in SH)]
Reported as:
Count of participants · Participants
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 1
ParticipantsRSVPreF3 GroupPlacebo Group
Nasal Congestion738
Rhinorrhea938
Sore Throat533
Cough (new or increased)1047
Sputum (new or increased)836
Shortness of breath or dyspnea (new or increased)429
Wheezing (new or increased)524
Crackles16
Rhonchi013
Respiratory rate ≥20 breaths/minute310
Low or decreased oxygen saturation18
Fever18
Feverishness216
Fatigue637
Body aches522
Headache427
Decreased appetite726
Need for oxygen supplementation04
Need for positive airway pressure therapy00
Need of other types of mechanical ventilation00
Other symptoms or signs212
SecondaryNumber of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 2

RSV infection was confirmed by RT-PCR, and the symptoms/signs and supportive therapy use associated with RT-PCR confirmed RSV A and/or RSV B LRTD episodes were reported. Fever was defined as a temperature ≥38.0°C by any route.

Time frame:
From Day 15 post-dose 2 administration up to end of Season 2 in SH (a median of approximately 11.9 months [11.9 months in NH and 7.5 months in SH])
Reported as:
Count of participants · Participants
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 2
ParticipantsPlacebo GroupRSV_1_dose GroupRSV_annual Group
Nasal Congestion902015
Rhinorrhea962019
Sore Throat791715
Cough (new or increased)1062120
Sputum (new or increased)951917
Shortness of breath or dyspnea (new or increased)721413
Wheezing (new or increased)561510
Crackles1923
Rhonchi3157
Respiratory rate ≥20 breaths/minute2150
Low or decreased oxygen saturation814
Fever1333
Feverishness4478
Fatigue861615
Body aches531511
Headache701714
Decreased appetite471311
Need for oxygen supplementation110
Need for positive airway pressure therapy010
Need of other types of mechanical ventilation000
Other symptoms or signs2835
SecondaryNumber of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 3

RSV infection was confirmed by RT-PCR, and the symptoms/signs and supportive therapy use associated with RT-PCR confirmed RSV A and/or RSV B LRTD episodes were reported. Fever was defined as a temperature ≥38.0°C by any route.

Time frame:
From start of Season 3 up to end of Season 3 in NH (a median of approximately 7 months)
Reported as:
Count of participants · Participants
Number of Participants With Each Reported Symptom/Sign and Supportive Therapy Use Associated With of RT-PCR Confirmed RSV A and/or B LRTD Episodes During Season 3
ParticipantsPlacebo GroupRSV_1_dose GroupRSV_annual Group
Nasal Congestion54134
Rhinorrhea50144
Sore Throat4295
Cough (new or increased)60156
Sputum (new or increased)53145
Shortness of breath or dyspnea (new or increased)3894
Wheezing (new or increased)3253
Crackles1020
Rhonchi1682
Respiratory rate ≥20 breaths/minute930
Low or decreased oxygen saturation1113
Fever600
Feverishness2283
Fatigue49136
Body aches39105
Headache41105
Decreased appetite33113
Need for oxygen supplementation010
Need for positive airway pressure therapy000
Need of other types of mechanical ventilation000
Other symptoms or signs2243
SecondaryNumber of Participants With RT-PCR Confirmed RSV A and/or B ARI and LRTD Episodes According to Severity

RSV A and/or B ARI and LRTD episodes were assessed as "mild", "moderate" or "severe" by the investigator after the single dose and after annual revaccination. Mild = an ARI/LRTD episode which is easily tolerated by the participant, causing minimal discomfort and not interfering with everyday activities. Moderate = an ARI/LRTD episode which is sufficiently discomforting to interfere with normal everyday activities. Severe = an ARI/LRTD episode which prevents normal, everyday activities.

Time frame:
Assessed during the study period (approximately 3 years for NH and 2.5-3 years for SH)
Reported as:
Count of participants · Participants
Number of Participants With RT-PCR Confirmed RSV A and/or B ARI and LRTD Episodes According to Severity
ParticipantsRSVPreF3 GroupPlacebo Group
Mild (Single dose)1649
Moderate (Single dose)29138
Severe (Single dose)328
Mild (Annual revaccination)1548
Moderate (Annual revaccination)23120
Severe (Annual revaccination)024
SecondaryRSVPreF3 Specific Immunoglobulin G(IgG) Antibody Concentrations

The RSVPreF3 IgG antibody concentrations are expressed as geometric mean concentrations (GMCs) in ELISA units per milliliter (EU/mL).

Time frame:
At pre-dose 1 (Day 1), Day 31 post-dose 1, pre-season 2 (approximately 10-17 months post Day 1 in NH; 12-21 months post Day 1 in SH) and pre-season 3 (approximately 24-27 months post Day 1, only in NH)
Reported as:
Geometric mean · EU/mL
RSVPreF3 Specific Immunoglobulin G(IgG) Antibody Concentrations
EU/mLPlacebo GroupRSV_1_dose GroupRSV_annual Group
Pre-dose 1 at day 17090.2 (6783.4 to 7410.9)6956.5 (6505.2 to 7439.2)7101.1 (6640.7 to 7593.4)
Post-dose 1 at day 317053.2 (6732.0 to 7389.8)89361.9 (83409.6 to 95738.9)93769.5 (87896.6 to 100034.8)
Pre-Season 27594.8 (7203.9 to 8007.0)24103.6 (22366.8 to 25975.3)24523.8 (22748.7 to 26437.4)
Pre-Season 38436.6 (7927.3 to 8978.7)21255.0 (19587.7 to 23064.2)28925.3 (26928.0 to 31070.7)
SecondaryRSV A Neutralizing Antibody Titers

The RSV A neutralizing antibody titers are expressed as geometric mean titers (GMTs).

Time frame:
At pre-dose 1 (Day 1), Day 31 post-dose 1, pre-season 2 (approximately 10-17 months post Day 1 in NH; 12-21 months post Day 1 in SH) and pre-season 3 (approximately 24-27 months post Day 1, only in NH)
Reported as:
Geometric mean · Titers
RSV A Neutralizing Antibody Titers
TitersPlacebo GroupRSV_1_dose GroupRSV_annual Group
Pre-dose 1 at day 1933.5 (881.8 to 988.4)899.8 (829.1 to 976.5)929.3 (852.6 to 1013.0)
Post-dose 1 at day 31880.8 (828.9 to 935.9)8915.5 (8080.6 to 9836.8)9652.4 (8727.5 to 10675.3)
Pre-Season 2865.8 (809.6 to 925.9)2535.9 (2284.7 to 2814.8)2918.4 (2594.5 to 3282.9)
Pre-Season 3977.9 (905.5 to 1056.0)2049.7 (1841.0 to 2282.1)2996.1 (2665.3 to 3368.1)
SecondaryRSV B Neutralizing Antibody Titers

RSV B neutralizing antibodies are expressed as GMTs.

Time frame:
At pre-dose 1 (Day 1), Day 31 post-dose 1, pre-season 2 (approximately 10-17 months post Day 1 in NH; 12-21 months post Day 1 in SH) and pre-season 3 (approximately 24-27 months post Day 1, only in NH)
Reported as:
Geometric mean · Titers
RSV B Neutralizing Antibody Titers
TitersPlacebo GroupRSV_1_dose GroupRSV_annual Group
Pre-dose 1 at day 11249.7 (1179.1 to 1324.5)1189.9 (1097.4 to 1290.2)1187.2 (1096.7 to 1285.2)
Post-dose 1 at day 311262.4 (1183.8 to 1346.2)9928.9 (9103.7 to 10829.0)10253.4 (9362.7 to 11228.9)
Pre-Season 21229.7 (1149.9 to 1315.1)2955.5 (2677.0 to 3262.9)2979.2 (2692.2 to 3296.9)
Pre-Season 3946.8 (873.5 to 1026.3)2054.5 (1829.9 to 2306.5)2515.3 (2249.9 to 2812.0)
SecondaryNumber of Participants With Any and Grade 3 Solicited Administration Site Adverse Events

Any solicited event is defined as the occurrence of any solicited adverse event (AE) regardless of intensity grade or relation to study vaccination. Grade 3 = an event which prevented normal, everyday activities. The assessed administration site events include pain, erythema and swelling.

Time frame:
During the 4-day follow up period after first vaccination (Day 1), second vaccination (administered pre-season 2) and after the third vaccination (administered pre-season 3 -only applicable for participants in NH])
Reported as:
Count of participants · Participants
Number of Participants With Any and Grade 3 Solicited Administration Site Adverse Events
ParticipantsPlacebo GroupRSV_1_dose GroupRSV_annual Group
Erythema, Dose 1, Any104130
Erythema, Dose 1, Grade 3002
Erythema, Dose 2, Any1131
Erythema , Dose 2, Grade 3003
Erythema, Dose 3 (NH), Any002
Erythema, Dose 3 (NH), Grade 3001
Pain, Dose 1, Any81267268
Pain, Dose 1, Grade 3063
Pain, Dose 2, Any5130169
Pain, Dose 2, Grade 3002
Pain, Dose 3 (NH), Any7325
Pain, Dose 3 (NH), Grade 3000
Swelling, Dose 1, Any72528
Swelling, Dose 1, Grade 3002
Swelling, Dose 2, Any2023
Swelling, Dose 2, Grade 3006
Swelling, Dose 3 (NH), Any012
Swelling, Dose 3 (NH), Grade 3000
SecondaryNumber of Participants With Any and Grade 3 Solicited Systemic Adverse Events

Any solicited event is defined as the occurrence of any solicited adverse event (AE) regardless of intensity grade or relation to study vaccination. Grade 3 = an event which prevented normal, everyday activities. The assessed solicited systemic events include arthralgia, fatigue, fever, headache and myalgia. Fever is defined as a temperature ≥ 38.0°C by any route. Grade 3 fever is defined as temperature \>39°C by any route.

Time frame:
During the 4-day follow up period after first vaccination (Day 1), second vaccination (administered pre-season 2) and after the third vaccination (administered pre-season 3 -only applicable for participants in NH])
Reported as:
Count of participants · Participants
Number of Participants With Any and Grade 3 Solicited Systemic Adverse Events
ParticipantsPlacebo GroupRSV_1_dose GroupRSV_annual Group
Arthralgia, Dose 1, Any567484
Arthralgia, Dose 1, Grade 3556
Arthralgia, Dose 2, Any482055
Arthralgia, Dose 2, Grade 3202
Arthralgia, Dose 3 (NH), Any525
Arthralgia, Dose 3 (NH), Grade 3000
Fatigue, Dose 1, Any141143153
Fatigue, Dose 1, Grade 3469
Fatigue, Dose 2, Any804498
Fatigue, Dose 2, Grade 3723
Fatigue, Dose 3 (NH), Any1289
Fatigue, Dose 3 (NH), Grade 3010
Fever, Dose 1, Any3144
Fever, Dose 1, Grade 3110
Fever, Dose 2, Any416
Fever, Dose 2, Grade 3200
Fever, Dose 3 (NH), Any100
Fever, Dose 3 (NH), Grade 3000
Headache, Dose 1, Any111116123
Headache, Dose 1, Grade 3065
Headache, Dose 2, Any604173
Headache, Dose 2, Grade 3412
Headache, Dose 3 (NH), Any965
Headache, Dose 3 (NH), Grade 3000
Myalgia, Dose 1, Any72127128
Myalgia, Dose 1, Grade 3357
Myalgia, Dose 2, Any522082
Myalgia, Dose 2, Grade 3303
Myalgia, Dose 3 (NH), Any537
Myalgia, Dose 3 (NH), Grade 3000
SecondaryNumber of Days With Solicited Administration Site Adverse Events
Time frame:
During the 4-day follow up period after first vaccination (Day 1), second vaccination (administered pre-season 2) and after the third vaccination (administered pre-season 3 -only applicable for participants in NH])
Reported as:
Median · Days
Number of Days With Solicited Administration Site Adverse Events
DaysPlacebo GroupRSV_1_dose GroupRSV_annual Group
Erythema, Dose 14.0 (2.0 to 4.0)3.0 (2.0 to 4.0)3.0 (2.0 to 4.0)
Erythema, Dose 24.0 (4.0 to 4.0)2.0 (2.0 to 2.0)3.0 (2.0 to 3.0)
Erythema, Dose 3 (NH)——3.0 (2.0 to 4.0)
Pain, Dose 11.0 (1.0 to 2.0)2.0 (1.0 to 3.0)2.0 (2.0 to 3.0)
Pain, Dose 21.0 (1.0 to 2.0)1.0 (1.0 to 2.0)2.0 (2.0 to 3.0)
Pain, Dose 3 (NH)2.0 (1.0 to 2.0)1.0 (1.0 to 2.0)2.0 (1.0 to 2.0)
Swelling, Dose 14.0 (2.0 to 8.0)3.0 (2.0 to 4.0)3.0 (2.0 to 4.5)
Swelling, Dose 22.0 (1.0 to 3.0)—3.0 (2.0 to 4.0)
Swelling, Dose 3 (NH)—49.0 (49.0 to 49.0)1.5 (1.0 to 2.0)
SecondaryNumber of Days With Solicited Systemic Adverse Events
Time frame:
During the 4-day follow up period after first vaccination (Day 1), second vaccination (administered pre-season 2) and after the third vaccination (administered pre-season 3 -only applicable for participants in NH])
Reported as:
Median · Days
Number of Days With Solicited Systemic Adverse Events
DaysPlacebo GroupRSV_1_dose GroupRSV_annual Group
Arthralgia, Dose 12.5 (1.0 to 4.0)2.0 (1.0 to 3.0)2.0 (1.0 to 3.0)
Arthralgia, Dose 22.0 (1.0 to 4.0)2.0 (1.0 to 3.0)1.0 (1.0 to 3.0)
Arthralgia, Dose 3 (NH)4.0 (3.0 to 4.0)2.0 (1.0 to 3.0)4.0 (1.0 to 4.0)
Fatigue, Dose 11.0 (1.0 to 3.0)2.0 (1.0 to 3.0)2.0 (1.0 to 3.0)
Fatigue, Dose 22.0 (1.0 to 4.0)1.5 (1.0 to 3.0)2.0 (1.0 to 3.0)
Fatigue, Dose 3 (NH)1.0 (1.0 to 2.0)2.5 (1.0 to 3.5)2.0 (1.0 to 2.0)
Fever, Dose 11.0 (1.0 to 2.0)1.0 (1.0 to 1.0)1.0 (1.0 to 1.5)
Fever, Dose 22.0 (1.5 to 3.0)1.0 (1.0 to 1.0)1.0 (1.0 to 4.0)
Fever, Dose 3 (NH)1.0 (1.0 to 1.0)——
Headache, Dose 11.0 (1.0 to 2.0)1.0 (1.0 to 2.0)1.0 (1.0 to 2.0)
Headache, Dose 22.0 (1.0 to 4.0)1.0 (1.0 to 2.0)1.0 (1.0 to 2.0)
Headache, Dose 3 (NH)1.0 (1.0 to 2.0)1.0 (1.0 to 1.0)2.0 (2.0 to 2.0)
Myalgia, Dose 11.5 (1.0 to 3.0)2.0 (1.0 to 3.0)2.0 (1.0 to 3.0)
Myalgia, Dose 22.0 (1.0 to 4.0)1.5 (1.0 to 2.0)2.0 (1.0 to 3.0)
Myalgia, Dose 3 (NH)2.0 (1.0 to 3.0)3.0 (1.0 to 3.0)2.0 (1.0 to 4.0)
SecondaryNumber of Participants With Any Unsolicited AEs

An unsolicited AE is defined as any AE reported in addition to those solicited during the clinical study. Also, any 'solicited' symptom with onset outside of the specified period of follow-up for solicited symptoms was reported as an unsolicited AE. Any= occurrence of the event regardless of intensity grade or relation to the study vaccination.

Time frame:
During the 30-day follow up period after first vaccination (Day 1), second vaccination (administered pre-season 2) and after the third vaccination (administered pre-season 3 -only applicable for participants in NH)
Reported as:
Count of participants · Participants
Number of Participants With Any Unsolicited AEs
ParticipantsPlacebo GroupRSV_1_dose GroupRSV_annual Group
Any unsolicited AE (post Dose 1)233421492136
Any unsolicited AE (post Dose 2)15708241456
Any unsolicited AE (post Dose 3)422233397
SecondaryNumber of Participants With Serious Adverse Events (SAEs)

An SAE is defined as any untoward medical occurrence that resulted in death, was life-threatening, required hospitalization or prolongation of existing hospitalization, resulted in disability/incapacity, was a congenital anomaly/birth defect in the offspring of a study participant, or in other situations that were considered serious per medical or scientific judgment. Any = occurrence of any SAE regardless of intensity grade or relation to study vaccination.

Time frame:
From the day of the vaccination up to 6 months after each vaccination (first vaccination: at Day 1, second vaccination: at pre-season 2 and the third vaccination: at pre-season 3 -only applicable for participants in NH])
Reported as:
Count of participants · Participants
Number of Participants With Serious Adverse Events (SAEs)
ParticipantsPlacebo GroupRSV_1_dose GroupRSV_annual Group
Any SAE (post Dose 1)541280268
Any SAE (post Dose 2)497239229
Any SAE (post Dose 3)1797573
SecondaryNumber of Participants With Potential Immune Mediated Diseases (pIMDs)

pIMDs aredefined as a subset of Adverse Events of Specific Interest (AESIs) that include autoimmune diseases and other inflammatory and/or neurologic disorders of interest which may or may not have an autoimmune aetiology. Any= occurrence of any pIMD regardless of intensity grade or relation to the study vaccination.

Time frame:
From the day of the vaccination up to 6 months after each vaccination (first vaccination: at Day 1, second vaccination: at pre-season 2 and the third vaccination: at pre-season 3 -only applicable for participants in NH])
Reported as:
Count of participants · Participants
Number of Participants With Potential Immune Mediated Diseases (pIMDs)
ParticipantsPlacebo GroupRSV_1_dose GroupRSV_annual Group
Any pIMDs (post Dose 1)392719
Any pIMDs (post Dose 2)391914
Any pIMDs (post Dose 3)13810
SecondaryNumber of Participants With Related SAEs

Related SAEs that occur throughout the study are assessed. Related SAEs= Any SAE related to investigational vaccine or related to study participation or to a GSK concomitant medication/vaccine as assessed by the investigator.

Time frame:
From Day 1 up to study end (approximately 3 years for NH and 2.5-3 years for SH)
Reported as:
Count of participants · Participants
Number of Participants With Related SAEs
ParticipantsPlacebo GroupRSV_1_dose GroupRSV_annual Group
Number of Participants With Related SAEs12812
SecondaryNumber of Participants With Fatal SAEs

Fatal SAEs that occur throughout the study are assessed. Fatal SAEs= Any SAEs leading to deaths.

Time frame:
From Day 1 up to study end (approximately 3 years for NH and 2.5-3 years for SH)
Reported as:
Count of participants · Participants
Number of Participants With Fatal SAEs
ParticipantsPlacebo GroupRSV_1_dose GroupRSV_annual Group
Number of Participants With Fatal SAEs265111120
SecondaryNumber of Participants With Related pIMDs

Related pIMD = pIMD assessed by the investigator as related to the study vaccination.

Time frame:
From Day 1 up to study end (approximately 3 years for NH and 2.5-3 years for SH)
Reported as:
Count of participants · Participants
Number of Participants With Related pIMDs
ParticipantsPlacebo GroupRSV_1_dose GroupRSV_annual Group
Number of Participants With Related pIMDs975

Adverse events

Collected over Solicited AEs: during the 4-day follow-up period after any vaccination and unsolicited AEs: during the 30-day follow-up period after any vaccination. SAEs and pIMDs from Day 1 up to 6 months after any vaccination. All cause mortality, Fatal SAEs, Related SAEs and Related pIMDs were collected throughout the study period (From Day 1 up to approximately 3 years for NH and 2.5-3 years for SH). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo Group265/12,503 (2.1%)1,660/12,503 (13.3%)5,837/12,503 (46.7%)
RSV_1_dose Group111/6,226 (1.8%)799/6,226 (12.8%)3,663/6,226 (58.8%)
RSV_annual Group120/6,243 (1.9%)796/6,243 (12.8%)3,826/6,243 (61.3%)
Most frequent serious events
Showing 10 of 1,034
Most frequent serious events
EventPlacebo GroupRSV_1_dose GroupRSV_annual Group
PneumoniaInfections and infestations80/1250337/622634/6243
OsteoarthritisMusculoskeletal and connective tissue disorders48/1250338/622621/6243
Atrial fibrillationCardiac disorders66/1250322/622631/6243
DeathGeneral disorders54/1250318/622628/6243
Myocardial infarctionCardiac disorders54/1250317/622616/6243
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders38/1250324/622618/6243
Cerebrovascular accidentNervous system disorders46/1250315/622622/6243
SyncopeNervous system disorders21/1250322/622613/6243
COVID-19Infections and infestations34/1250321/622619/6243
Prostate cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps)39/1250320/622615/6243
Most frequent other events
Showing 10 of 1,741
Most frequent other events
EventPlacebo GroupRSV_1_dose GroupRSV_annual Group
Injection site painGeneral disorders424/125031379/62261713/6243
HeadacheNervous system disorders710/12503594/6226664/6243
COVID-19Infections and infestations1178/12503600/6226601/6243
FatigueGeneral disorders410/12503394/6226453/6243
Injection site erythemaGeneral disorders56/12503291/6226449/6243
Injection site swellingGeneral disorders38/12503208/6226347/6243
MyalgiaMusculoskeletal and connective tissue disorders205/12503228/6226307/6243
Upper respiratory tract infectionInfections and infestations526/12503244/6226243/6243
ArthralgiaMusculoskeletal and connective tissue disorders299/12503226/6226261/6243
PyrexiaGeneral disorders85/12503144/6226197/6243

Baseline characteristics

Age, Continuous
Age, Continuous(YEARS)RSVPreF3 GroupPlacebo GroupTotal
Mean69.5 ± 6.569.6 ± 6.469.5 ± 6.5
Sex: Female, Male
Sex: Female, Male(Participants)RSVPreF3 GroupPlacebo GroupTotal
Female6489642912918
Male5980607412054
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RSVPreF3 GroupPlacebo GroupTotal
Asian9539561909
Black or African American106411012165
White9889993619825
All Other Races554196
Other508469977
08

Study locations

277 sites
  • GSK Investigational Site
    Birmingham, Alabama 35205, United States
  • GSK Investigational Site
    Birmingham, Alabama 35211, United States
  • GSK Investigational Site
    Huntsville, Alabama 35802, United States
  • GSK Investigational Site
    Phoenix, Arizona 85306, United States
  • GSK Investigational Site
    Tucson, Arizona 85741, United States
  • GSK Investigational Site
    Cerritos, California 90703, United States
  • GSK Investigational Site
    Laguna Hills, California 92653, United States
  • GSK Investigational Site
    Coral Gables, Florida 33134, United States
  • GSK Investigational Site
    Fort Myers, Florida 33912, United States
  • GSK Investigational Site
    Jacksonville, Florida 32205, United States
  • GSK Investigational Site
    Lake City, Florida 32055, United States
  • GSK Investigational Site
    Melbourne, Florida 32934, United States
  • GSK Investigational Site
    Miami, Florida 33174, United States
  • GSK Investigational Site
    Orlando, Florida 32806, United States
  • GSK Investigational Site
    Pinellas Park, Florida 33781, United States
  • GSK Investigational Site
    The Villages, Florida 32162, United States
  • GSK Investigational Site
    Weeki Wachee, Florida 34607, United States
  • GSK Investigational Site
    West Palm Beach, Florida 33409, United States
  • GSK Investigational Site
    Atlanta, Georgia 30328, United States
  • GSK Investigational Site
    Chicago, Illinois 60602, United States
  • GSK Investigational Site
    Evansville, Indiana 47714, United States
  • GSK Investigational Site
    Mishawaka, Indiana 46544, United States
  • GSK Investigational Site
    El Dorado, Kansas 67042, United States
  • GSK Investigational Site
    Newton, Kansas 67114, United States
  • GSK Investigational Site
    Wichita, Kansas 67205, United States
  • GSK Investigational Site
    Wichita, Kansas 67207, United States
  • GSK Investigational Site
    Lexington, Kentucky 40509, United States
  • GSK Investigational Site
    Rockville, Maryland 20854, United States
  • GSK Investigational Site
    Richfield, Minnesota 55423, United States
  • GSK Investigational Site
    Kansas City, Missouri 64114, United States
  • GSK Investigational Site
    St Louis, Missouri 63141, United States
  • GSK Investigational Site
    Omaha, Nebraska 68134, United States
  • GSK Investigational Site
    Henderson, Nevada 89052, United States
  • GSK Investigational Site
    Binghamton, New York 31406, United States
  • GSK Investigational Site
    Jamaica, New York 10017, United States
  • GSK Investigational Site
    Rochester, New York 14609, United States
  • GSK Investigational Site
    Hickory, North Carolina 28601, United States
  • GSK Investigational Site
    Rocky Mount, North Carolina 27804, United States
  • GSK Investigational Site
    Salisbury, North Carolina 28144, United States
  • GSK Investigational Site
    Statesville, North Carolina 28117, United States
  • GSK Investigational Site
    Winston-Salem, North Carolina 27103, United States
  • GSK Investigational Site
    Akron, Ohio 44311, United States
  • GSK Investigational Site
    Centerville, Ohio 45459, United States
  • GSK Investigational Site
    Cincinnati, Ohio 45236, United States
  • GSK Investigational Site
    Columbus, Ohio 43212, United States
  • GSK Investigational Site
    Erie, Pennsylvania 16508, United States
  • GSK Investigational Site
    Pittsburgh, Pennsylvania 15236, United States
  • GSK Investigational Site
    Anderson, South Carolina 29621, United States
  • GSK Investigational Site
    Mt. Pleasant, South Carolina 29405, United States
  • GSK Investigational Site
    Knoxville, Tennessee 37912, United States
  • GSK Investigational Site
    Memphis, Tennessee 38119, United States
  • GSK Investigational Site
    Dallas, Texas 75234, United States
  • GSK Investigational Site
    Fort Worth, Texas 76104, United States
  • GSK Investigational Site
    Houston, Texas 77008, United States
  • GSK Investigational Site
    Houston, Texas 77055, United States
  • GSK Investigational Site
    Keller, Texas 76248, United States
  • GSK Investigational Site
    San Antonio, Texas 78229, United States
  • GSK Investigational Site
    Layton, Utah 84041, United States
  • GSK Investigational Site
    Murray, Utah 84106, United States
  • GSK Investigational Site
    Norfolk, Virginia 23502, United States
  • GSK Investigational Site
    Botany, New South Wales 2217, Australia
  • GSK Investigational Site
    Coffs Harbour, New South Wales 2450, Australia
  • GSK Investigational Site
    Darlinghurst, New South Wales 2010, Australia
  • GSK Investigational Site
    Morayfield, Queensland 4506, Australia
  • GSK Investigational Site
    Taringa, Queensland 4068, Australia
  • GSK Investigational Site
    Tarragindi, Queensland 4121, Australia
  • GSK Investigational Site
    Camberwell, Victoria 3124, Australia
  • GSK Investigational Site
    Geelong, Victoria 3220, Australia
  • GSK Investigational Site
    Spearwood, Western Australia 6163, Australia
  • GSK Investigational Site
    Aalst, 9300, Belgium
  • GSK Investigational Site
    Alken, 3570, Belgium
  • GSK Investigational Site
    Edegem, 2650, Belgium
  • GSK Investigational Site
    Erpent, 5101, Belgium
  • GSK Investigational Site
    Genk, 3600, Belgium
  • GSK Investigational Site
    Ghent, 9000, Belgium
  • GSK Investigational Site
    Ieper, 8900, Belgium
  • GSK Investigational Site
    Linkebeek, 3500, Belgium
  • GSK Investigational Site
    Linkebeek, 3545, Belgium
  • GSK Investigational Site
    Linkebeek, 4987, Belgium
  • GSK Investigational Site
    Linkebeek, 6534, Belgium
  • GSK Investigational Site
    Linkebeek, 6887, Belgium
  • GSK Investigational Site
    Linkebeek, 9690, Belgium
  • GSK Investigational Site
    Mechelen, 2800, Belgium
  • GSK Investigational Site
    Tremelo, 3120, Belgium
  • GSK Investigational Site
    Edmonton, Alberta T5A 4L8, Canada
  • GSK Investigational Site
    New Westminster, British Columbia V3L 3W4, Canada
  • GSK Investigational Site
    Surrey, British Columbia V3S 2N6, Canada
  • GSK Investigational Site
    Vancouver, British Columbia V6Z 2T1, Canada
  • GSK Investigational Site
    Victoria, British Columbia V8V 3M9, Canada
  • GSK Investigational Site
    Victoria, British Columbia V8V 4A1, Canada
  • GSK Investigational Site
    Halifax, Nova Scotia B3J 3G9, Canada
  • GSK Investigational Site
    Truro, Nova Scotia B2N 1L2, Canada
  • GSK Investigational Site
    Greater Sudbury, Ontario P3C 1X3, Canada
  • GSK Investigational Site
    London-Ontario, Ontario N5W 6A2, Canada
  • GSK Investigational Site
    Ottawa, Ontario K1H 8L6, Canada
  • GSK Investigational Site
    Sarnia, Ontario N7T 4X3, Canada
  • GSK Investigational Site
    Toronto, Ontario M9W 4L6, Canada
  • GSK Investigational Site
    Chicoutimi, Quebec G7H 7Y8, Canada
  • GSK Investigational Site
    Mirabel, Quebec J7J 2K8, Canada
  • GSK Investigational Site
    Pointe-Claire, Quebec H9R 4S3, Canada

Showing the first 100 of 277 sites across 17 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Ison MG, Papi A, Athan E, Feldman RG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Verheust C, Dezutter N, Gruselle O, Fissette L, David MP, Kostanyan L, Hulstrom V, Olivier A, Van der Wielen M, Descamps D; AReSVi-006 Study Group. Efficacy and Safety of Respiratory Syncytial Virus (RSV) Prefusion F Protein Vaccine (RSVPreF3 OA) in Older Adults Over 2 RSV Seasons. Clin Infect Dis. 2024 Jun 14;78(6):1732-1744. doi: 10.1093/cid/ciae010. PubMed 38253338 ↗
  • Tajima K, Zarkadoulas E, Simons J, Kurai D, Grace M, Graham J, Ho Y, Verelst F. Cost-effectiveness of the adjuvanted respiratory syncytial virus prefusion F protein (RSVPreF3) vaccine in Japanese adults aged 50-59 years at increased risk of severe RSV disease and those aged >/=60 years. Expert Rev Vaccines. 2026 Dec;25(1):2626921. doi: 10.1080/14760584.2026.2626921. Epub 2026 Feb 11. PubMed 41637686 ↗
  • Ison MG, Papi A, Athan E, Feldman RG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Cuadripani S, Deraedt Q, Dezutter N, Gerard C, Fissette L, Xavier S, David MP, Olivier A, Van der Wielen M, Descamps D; AReSVi-006 study group. Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial. Lancet Respir Med. 2025 Jun;13(6):517-529. doi: 10.1016/S2213-2600(25)00048-7. Epub 2025 Apr 14. PubMed 40245915 ↗
  • Sanchez-Martinez ZV, Alpuche-Lazcano SP, Stuible M, Durocher Y. CHO cells for virus-like particle and subunit vaccine manufacturing. Vaccine. 2024 Apr 11;42(10):2530-2542. doi: 10.1016/j.vaccine.2024.03.034. Epub 2024 Mar 19. PubMed 38503664 ↗
  • Kurai D, Mizukami A, Preckler V, Verelst F, Molnar D, Matsuki T, Ho Y, Igarashi A. The potential public health impact of the respiratory syncytial virus prefusion F protein vaccine in people aged >/=60 years in Japan: results of a Markov model analysis. Expert Rev Vaccines. 2024 Jan-Dec;23(1):303-311. doi: 10.1080/14760584.2024.2323128. Epub 2024 Mar 1. PubMed 38426479 ↗
  • Curran D, Matthews S, Cabrera ES, Perez SN, Breva LP, Ramet M, Helman L, Park DW, Schwarz TF, Melendez IMG, Schaefer A, Roy N, Stephan B, Molnar D, Kostanyan L, Powers JH 3rd, Hulstrom V; Members of the AReSVi-006 Study Group. The respiratory syncytial virus prefusion F protein vaccine attenuates the severity of respiratory syncytial virus-associated disease in breakthrough infections in adults >/=60 years of age. Influenza Other Respir Viruses. 2024 Feb 3;18(2):e13236. doi: 10.1111/irv.13236. eCollection 2024 Feb. PubMed 38314063 ↗
  • Feldman RG, Antonelli-Incalzi R, Steenackers K, Lee DG, Papi A, Ison MG, Fissette L, David MP, Marechal C, Van der Wielen M, Kostanyan L, Hulstrom V; AReSVi-006 Study Group. Respiratory Syncytial Virus Prefusion F Protein Vaccine Is Efficacious in Older Adults With Underlying Medical Conditions. Clin Infect Dis. 2024 Jan 25;78(1):202-209. doi: 10.1093/cid/ciad471. PubMed 37698366 ↗
  • Papi A, Ison MG, Langley JM, Lee DG, Leroux-Roels I, Martinon-Torres F, Schwarz TF, van Zyl-Smit RN, Campora L, Dezutter N, de Schrevel N, Fissette L, David MP, Van der Wielen M, Kostanyan L, Hulstrom V; AReSVi-006 Study Group. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults. N Engl J Med. 2023 Feb 16;388(7):595-608. doi: 10.1056/NEJMoa2209604. PubMed 36791160 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — GSK will assess requests from qualified researchers for anonymized individual patient-level data and related study documents. Data sharing is subject to certain criteria, conditions, and exceptions. For further information, refer tohttps://www.gsk-studyregister.com/About_GSK_Patient_Level_Data_Sharing_Final_13July2023.pdf.

Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months but an extension can be granted, when justified, for up to another 12 months.

Data sharing details ↗ · www.gsk-studyregister.com

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2021 to primary completion in Apr 2022, 10 months.

Results were first posted in Aug 2023, 1 year 3 months after primary completion.

Of 27 industry-sponsored phase 3 interventional studies under Respiratory Syncytial Virus Infections, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 19. This study's 10 months is above that.

Counting every sponsor, half of 32 studies reached it within 8 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 29, 2021
First posted
May 14, 2021
StartActual
May 25, 2021
Primary completionActual
Apr 11, 2022
CompletionActual
May 31, 2024
Results first posted
Aug 4, 2023
Last update
Jul 31, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 31, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT04886596
Lead sponsor
GlaxoSmithKline
Responsible party
Sponsor
First posted
May 14, 2021
Start date
May 25, 2021
Primary completion
Apr 11, 2022
Completion
May 31, 2024
Results posted
Aug 4, 2023
Last update
Jul 31, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Arexvy

Start the discussion